Nordic Bioscience   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Herlev Denmark (1991)

Organization Overview

First Clinical Trial
2004
NCT00259246
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aditech Pharma AB | NBCD A/S | Nordic Bioscience A/S | Nordic Bioscience Clinical Development | Nordic Bioscience Clinical Studies A/S | Nordic Biotic Sp. z o.o. | Rheoscience A/S

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Osteoporosis (Phase 3)

Osteoporosis, Postmenopausal (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 20